CHEMIOTERAPIA DEL CARCINOMA MAMMARIO AVANZATO.
QUALE FARMACO? QUALE MODALITÁ?
I. Puliafito, A. Prestifilippo, G. Blanco, D. Sciacca, D. Giuffrida
Vol.2 (2017), issue 4, pag.20-23
| Received | 13/11/2017 |
| Accepted for pubblication | 29/11/2017 |
| Published | Dec. 2017 |
| Review by | Single-blind |
ABSTRACT
This paper evaluates the role of chemotherapy in elderly patients with advanced breast cancer. Clinical trials demonstrate that risk of mortality increases in patients with age> 70 at start of therapy but age is not the only prognostic factor causing a short survival; negative HER2 or hormone receptor status, multiple metastatic sites, high grade and comorbidities influence prognosis. Several agents are used as monochemotherapy with a good response rate and poliche-
motherapy is a valid option in selected patients. Metronomic chemotherapy represents a valid option with a good efficacy and tolerability. Clinical trials are needed to confirm the role of chemotherapy in elderly women with metastatic breast cancer.